Eurofins MWG Operon, Genomatix Software offer joint services to develop complete human exome array

NewsGuard 100/100 Score

Joint services offered for human exome targeted re-sequencing based on Roche NimbleGen format

Eurofins MWG Operon, an expert in next generation sequencing (NGS) and Certified Service Provider for Roche NimbleGen sequence capture, together with Genomatix Software GmbH, a leading company in complex analysis and interpretation of such NGS data, announce that they have developed a complete human exome array, based on Roche NimbleGen sequence capture technology.

"We are pleased to offer this comprehensive service for human exome capture, targeted re-sequencing and data interpretation. The development of the new exome array was necessary, as currently available versions of human whole-exome capture products do not include or do not efficiently capture many medically relevant genes, so that researchers might miss important information." says Bruno Poddevin, Eurofins Senior Vice President, Genomic Services.

Klaus May, Chief Business Officer of Genomatix, says: "Based on the latest human reference genome sequence hg19/NCBI37/GRCh37 and our proprietary ElDorado extended genome annotation 02-2010 we developed a human exome with 282,363 target regions, representing 240,402 exonic regions. We included splice sites and added 83,246 proximal promoter regions plus 678 microRNAs in order to allow the researcher to obtain the most comprehensive picture that exon capturing technology allows today. The combined expertise of Eurofins and Genomatix enables us to offer the most advanced whole exome analysis service available to date."

A very recent comparison study by Kevin Jacobs, Director of Scientific Operations of Bioinformatics at the National Cancer Institute, presented at the June "Beyond Sequencing Conference" in San Francisco, showed that between 17 percent and 23 percent of human coding sequences are not targeted by current exome capturing systems, missing out several medically important genes.

The new proprietary exome is filling that gap. It is contained on two 2.1M NimbleGen arrays and is usually sequenced with two channels of a GA IIx run with 108bp chemistry.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions